Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Statins, What Next?

This article was originally published in Start Up

Executive Summary

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.

You may also be interested in...



Life Without Plavix: Sanofi Highlights Next Generation Drugs

Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.

Aterovax SA

Current treatments for atherosclerosis use markers and therapeutic targets that are consequences of the disease. Aterovax SA is attempting a more direct route. By basing its research and pipeline on sPLA2, a family of secreted phospholipases that are mediators in the inflammatory process involved in atherosclerosis, it hopes to create products that are either predictive of cardiovascular disease rather than simply diagnostic, or that can stop the development of unstable atherosclerotic plaques.

Merck Taking Aggressive Approach To Cardiovascular Development

Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel